Marizomib

Generic Name
Marizomib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C15H20ClNO4
CAS Number
437742-34-2
Unique Ingredient Identifier
703P9YDP7F
Background

Marizomib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Malignant Glioma, among others.

Associated Conditions
-
Associated Therapies
-

Marizomib Central Nervous System (CNS)

First Posted Date
2021-09-20
Last Posted Date
2024-07-16
Lead Sponsor
Dana-Farber Cancer Institute
Registration Number
NCT05050305
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Expanded Access for Marizomib

Conditions
First Posted Date
2020-11-25
Last Posted Date
2020-11-25
Lead Sponsor
Celgene
Registration Number
NCT04644107
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Bristol Myers Squibb, Summit, New Jersey, United States

Phase I Study of Marizomib + Panobinostat for Children With DIPG

First Posted Date
2020-04-10
Last Posted Date
2024-02-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
4
Registration Number
NCT04341311
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Boston Children's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2018-11-01
Last Posted Date
2022-07-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
4
Registration Number
NCT03727841
Locations
๐Ÿ‡บ๐Ÿ‡ธ

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

First Posted Date
2017-11-17
Last Posted Date
2024-07-12
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
749
Registration Number
NCT03345095
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of California, San Francisco, California, United States

๐Ÿ‡จ๐Ÿ‡ฆ

Saint John Regional Hospital, Saint John, New Brunswick, Canada

๐Ÿ‡จ๐Ÿ‡ญ

University Hospital of Geneva, Geneva, Switzerland

and more 78 locations

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

First Posted Date
2014-04-03
Last Posted Date
2017-11-22
Lead Sponsor
Celgene
Target Recruit Count
38
Registration Number
NCT02103335
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Chicago Medical Center, Chicago, Illinois, United States

๐Ÿ‡บ๐Ÿ‡ธ

Karmanos Cancer Center, Detroit, Michigan, United States

and more 3 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath